USPTO serial 79304462
G2B GATE2BRAIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 7, 2022
- Examiner
- MCCARTHY, BRIDGET ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with G2B GATE2BRAIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Justin R. Young
Justin R. Young DTL Ltd.160 North Wacker DriveChicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical compositions and materials for scientific use, namely, chemicals for use in biomedicine and pharmaceutical sciences; proteins for use in science and industry; proteins for pharmaceutical industry; chemical substances, biochemical substances and natural elements, namely, peptides and proteins for use in the manufacture of pharmaceutical and veterinary products; chemical preparations for scientific use other than for medical or veterinary use | ACTIVE | — |
| 005 | Pharmaceutical products for the treatment of brain related diseases and conditions; medicinal and veterinary products and preparations, namely, preparations for the treatment of central nervous system diseases and conditions; regulatory proteins for medical use for the treatment of central nervous system diseases and conditions; synthetic peptides for pharmaceutical use for the treatment of brain diseases and conditions; vaccines; drug delivery agents in the form of suspension, injectable solution, micelles, micellar solution, solid powder, liophilized powder that facilitate the administering of medicines across biological barriers; pharmaceutical agents acting on metabolism; therapeutic products of bacterial origin, namely, small molecules, proteins and peptides for the treatment of brain diseases; biological preparations for medical use for the treatment of brain diseases and conditions; probiotic bacterial formulations for medical use for the treatment of brain diseases and conditions; stem cells for medical use; nutraceuticals for therapeutic use for the treatment of brain diseases and conditions; pharmaceutical preparations for activating cellular function; chemico-pharmaceutical preparations for the treatment of brain diseases and conditions; dietetic preparations and supplements adapted for medical purposes; nutritional supplements; nutritional supplements for veterinary use; dietary supplements for veterinary use | ACTIVE | — |
| 042 | Scientific services, namely, scientific research and testing in the field of drug delivery across biological barriers; research services, namely, pharmaceutical and biomedical research services; research regarding pharmaceutical products, namely, pharmaceutical research services; scientific research in the field of chemistry; biotechnological research; biochemical research and analysis; research and development services in the field of bacteriology; research and development services in the field of vaccines; medical and pharmacological research; scientific research in the fields of biochemistry and biotechnology; food research; stem cell research; development of pharmaceutical products; conducting clinical trials for others relating to pharmaceutical products; development of pharmaceutical preparations and medicines; bacteriological research and consultancy; scientific consultancy relating to research and development in the field of therapeutics; providing information and data services about medical and veterinary research and development; scientific consultancy services; provision of medical research information regarding results of clinical trials relating to pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Gate2Brain S.L.
- Other trademarks owned by Gate2Brain S.L.
- Other trademarks owned by Gate2Brain S.L.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named G2B GATE2BRAIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 7, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 23, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 22, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 7, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 7, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 7, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 22, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 22, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 2, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 2, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 2, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 14, 2022 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 14, 2022 | ALIE | ASSIGNED TO LIE | — |
| Feb 11, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 11, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 11, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 11, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 11, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 14, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 14, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 14, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 17, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 17, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 17, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 17, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 1, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 14, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 14, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 9, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 8, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 23, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 18, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |